Successful treatment of cutaneous leishmaniasis using systemic interferon-gamma

Developmental Neuroscience

Volumn 192, Issue 1, 1996, Pages 56-60

  Kolde, G ^a   Luger, T ^a   Sorg, C ^a   Sunderkutier S ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Calcium binding protein; Interferon gamma; Leishmaniasis; Macrophage phenotypes; MRP 14; Therapy

Indexed keywords

GAMMA INTERFERON;

ARTICLE; CASE REPORT; CHILD; GRANULOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MONOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SKIN ULCER; SUBCUTANEOUS DRUG ADMINISTRATION; UPPER EYELID;

EID: 0030043626     PISSN: 03785866     EISSN: 14219859     Source Type: Journal    
DOI: 10.1159/000246316     Document Type: Article

References (28)

1. Lainson R, Shaw JI: Evolution, classification and geographical distribution: in Peters W. Kil-lick-Kendrick R (eds): The Leishmaniases in Biology and Medicine. New York. Academic Press, 1987, pp 1-119.
2. Mauel J: Macrophage-parasite interactions in Leishmania infections. J Leukocyte Biol 1990: 47:187-193.
3. Farah FS. Malak JA: Cutaneous leishmaniasis. Arch Dermatol 1971:103:467-474.
4. Magill AJ, Gögl M. Gasser RA Jr. Sun W. Oster CN: Visceral infection caused by Leishmania tropica in veterans of operation desert storm. N Engl J Med 1993:328:1383-1387.
5. Koff AB. Rosen T: Treatment of cutaneous leishmaniasis. J Am Acad Dermatol 1994:31: 693-708.
6. Dogra J: Current therapies for treatment of cutaneous leishmaniasis in India. Infection 1992;20:189-191.
7. Berman JD: Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis 1988; 10: 560-586.
8. Reed SG. Scott P: T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 1993:5:524-531.
9. Sunderkotter C. Kunz M. Steinbrink K. et al: Resistance of mice to experimental leishmaniasis is associated w ith more rapid appearance of mature macrophages in vitro and in vivo. J Immunol 1993;151:4891-4901.
10. James SL, Nacy C: Effector functions of activated macrophages against parasites. Curr Opin Immunol 1993;5:518-523.
11. Muller I, Garcia-Sanz JA. Titus R. et al: Analysis of the cellular parameters of the immune responses contributing to resistance and susceptibility of mice to infection with the intracellular parasite, Leishmania major; in Moller G (ed): Immunological Reviews, No 112, Immunobiology of Parasites. Copenhagen, Munksgaard, 1989, pp 95-113.
12. Odink K, Cerletti N, Briiggen J, et al: Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987; 330:80-82.
13. Hessian PA. Edgeworth J, Hogg N: MRP-8 and MRP-14, two abundant Ca-binding proteins of neutrophils and monocytes. J Leukocyte Biol 1993:53:197-204.
14. Goebeler M, Roth J, Teigeikamp S, Sorg C: The monoclonal antibody MAC387 detects an epitope on the calcium-binding protein MRPI4. J Leukocyte Biol 1994;55:259-261.
15. Badarô R, Falcoff E, Badaro FS, et al: Treatment of visceral leishmaniasis with pentavalent antimony and interferon-'/. N Engl J Med 1990:322:16-21.
16. Badarô R, Johnson WD Jr.: The role of interferon-'/in the treatment of visceral and diffuse cutaneous leishmaniasis. J Infect Dis 1993; 167 (suppl):S13-S17.
17. Squires KE, Rosenkaimer F, Sherwood JA, Form AL, Were JB, Murray HW: Immuno-chemotherapy for visceral leishmaniasis: A controlled pilot trial of antimony versus antimony plus interferon-gamma. Am J Trop Med Hyg 1993:48:666-669.
18. Boltasso O, Cabrini J. Falcofl' R: Successful treatment of an antimony-resistant American mucocutaneous leishmaniasis: A case report. Arch Dermatol 1992;128:996-997.
19. Kurkcuoglu N. Tandogdu R: Interferon gamma therapy for cutaneous leishmaniasis. Arch Dermatol 1990:126:831-832.
20. Harms G, Zwingenberger K. Chchadc AK. et al: Effects of intradermal gamma-interferon in cutaneous leishmaniasis. Lancet 1989:vol i: 1287-1292.
21. Harms G. Chchadé AK. Douba M. et al: A randomized trial comparing a pentavalent antimo-nial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis. Trans R Soc Trap Med Hyg 1991:85: 214-216.
22. Martinez, S. Marr J J: Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992;326:741-744.
23. Bclosevic M, Davis CE. Meitzer MS. Nacy CA: Regulation of activated macrophage antimicrobial activities. Identification of lym-phokincs that cooperate with IFN-yfor induction of resistance to infection. J Immunol 1988:141:890-896.
24. Lehn M. Weiser WY. Engelhorn SE. Gillis S. Remold I IG: IL-4 inhibits H, C, production and antileishmanial capacity of human cultured monocytes mediated by IFN-y. J Immunol 1989;143:3020-3024.
25. Muller KM. Hauser C: The biological and clinical significance of helperT-ccll subsets in the human. Exp Dermatol 1992:1:161-169.
26. Greil J. Bodendorfer B. Rollinghoff M. Sol-bach W: Application of recombinant granulocyte-macrophage colony-stimulating factor has a detrimental effect in experimental murine leishmaniasis. Eur J Immunol 1988:18: 1527-1533.
27. Feng ZY. Louis J. Kindler V. et al: Aggravation of experimental cutaneous leishmaniasis in mice by administration of interleukin 3. Eur J Immunol 1988:18:1245-1251.
28. Gradoni L. Gramiccia M: Fatal visceral disease caused by a dermotropic Leishmania in a patient with human immunodeficiency virus infection. J Infect 1990:20:180-182.